Theranos Withdraws Zika Blood Test

The embattled company failed to include proper safeguards, according to federal regulators.

By | September 1, 2016

Elizabeth Holmes, CEO and founder of TheranosWIKIMEDIA, GLENN FAWCETTTheranos’s best hope for a comeback—a blood-based test called miniLab—is already in hot water. According to a news release, Theranos researchers demonstrated the success of their Zika blood test on the device, but officials at the US Food and Drug Administration (FDA) now say that the company did not implement proper patient-safety protocols, The Wall Street Journal (WSJ) reported. Theranos, which made headlines earlier this year for troubles with substandard laboratory conditions and allegations of criminal activity, has now withdrawn its request for emergency clearance of the Zika test.

“We hope that our decision to withdraw the Zika submission voluntarily is further evidence of our commitment to engage positively with the agency,” Dave Wurtz, Theranos’s vice president of regulatory, quality and clinical affairs, told WSJ.

When CEO Elizabeth Holmes, who was banned from operating a lab for two years after the company was caught selling inaccurate blood tests to consumers, announced the miniLab’s launch at the American Association for Clinical Chemistry (AACC) conference earlier this month (August 1), she claimed that the blood-based test would one day be able to run 160 different assays, from lipid panels to Zika tests. That same day, the company put out a press release stating that it had already tested the device on blood samples collected by finger pricks from patients, including those in the Dominican Republic, and had submitted “validation data for this Zika assay to the FDA for an Emergency Use Authorization.” But according to sources cited by the WSJ, some data in that submission had not followed review-board-approved protocols.

“As with the last phases, Theranos’ implementation of the miniLab may have played too fast and loose with federal regulations,” The Verge reported.

According to WSJ, Theranos investors received an email from the company last Saturday stating that it plans to collect additional data and resubmit an FDA application for emergency clearance of the Zika test, and that it would eventually do the same for an Ebola test.

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. Man Receives First In Vivo Gene-Editing Therapy
  2. Researchers Build a Cancer Immunotherapy Without Immune Cells
  3. Long-term Study Finds That the Pesticide Glyphosate Does Not Cause Cancer
  4. Research Links Gut Health to Neurodegeneration
    The Nutshell Research Links Gut Health to Neurodegeneration

    Rodent studies presented at the Society for Neuroscience meeting this week tie pathologies in the gastrointestinal tract or microbiome composition with Parkinson’s and Alzheimer’s diseases.

RayBiotech